A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C—C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF). A randomized, double‐blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fat...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman, Scott L., Ratziu, Vlad, Harrison, Stephen A., Abdelmalek, Manal F., Aithal, Guruprasad P., Caballeria, Juan, Francque, Sven, Farrell, Geoffrey, Kowdley, Kris V., Craxi, Antonio, Simon, Krzysztof, Fischer, Laurent, Melchor‐Khan, Liza, Vest, Jeffrey, Wiens, Brian L., Vig, Pamela, Seyedkazemi, Star, Goodman, Zachary, Wong, Vincent Wai‐Sun, Loomba, Rohit, Tacke, Frank, Sanyal, Arun, Lefebvre, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947654/
https://www.ncbi.nlm.nih.gov/pubmed/28833331
http://dx.doi.org/10.1002/hep.29477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947654/
https://www.ncbi.nlm.nih.gov/pubmed/28833331
http://dx.doi.org/10.1002/hep.29477

Ejemplares similares